Grants Search Results

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Nurse to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Assistant to ensure that more kids can be treated on early-phase clinical trials, often their best hope for a cure.

This grant funds a Nurse Practitioner who enrolls and provides services for patients in the Childhood Cancer Survivorship Program. The program also provides critical patient data for survivorship researchers.

This grant funds a Clinical Research Nurse who will also act as the Adolescent and Young Adult (AYA) Liaison to ensure that more kids, adolescents, and young adults can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports the research team developing the Hematologic Malignancies Program at Connecticut Children's Medical Center. The program will provide clinical care for hematologic malignancy patients and enroll them on clinical trials, often their best hope for a cure.

This grant supports the Defeat Pediatric Brain Tumors Research Collaborative, focused on helping kids with high-grade gliomas. The Collaborative is made up of four teams that study new targets for medicines, search brain cancer biomarkers, and conduct clinical trials, all to accelerate scientific discovery in pediatric brain tumors.

Based on progress to date, Dr. Parameswaran was awarded new grants in 2019 and 2020 to fund additional years of this Scholar grant. Acute Myeloid Leukemia (AML) is the second most common acute leukemia in children, and current treatment strategies are inadequate to cure AML. Dr. Parameswaran is developing a new strategy using Natural Killer cells, which are a type of white blood cells with potential to kill cancer cells. Cancer cells often produce a protein that makes Natural Killer cells less active, which helps the cancer cells escape from NK cell-mediated killing. Dr. Parameswaran and her team are developing methods to stop this NK cell inactivation and thereby improve NK cell function to treat pediatric AML.

This grant is generously supported by Rays of Hope, a St. Baldrick's Hero Fund created in memory of Rayanna Marrero. She was a happy 3 year old when she was diagnosed with Acute Lymphoblastic Leukemia. She battled ALL and won but a treatment induced secondary cancer claimed her life at age eight. Rayanna had an amazing attitude and loved life. She, like so many kids facing childhood cancer, did not allow it to define who she was. This Hero Fund aspires to give hope to kids fighting cancer through research.

Children continue to die from leukemia because malignant cells overcome chemotherapy by turning off normal genetic safety checkpoints. Dr. Nalepa has found that loss of the same checkpoints makes cancer growth dependent on other genes, which represent possible anti-cancer targets. Dr. Nalepa is investigating the weak points of the cancer cells, and testing these precision-medicine strategies in new models of childhood leukemia. Dr. Nalepa will use the results of this testing to generate personalized therapy driven by cancer-specific mutations that will be more effective and less toxic for children who suffer from leukemia.

This grant funds a doctoral student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

Based on progress to date, Dr. Shah was awarded a new grant in 2019 to fund an additional year of this Scholar grant. Finding a donor for a bone marrow transplant can be difficult for patients that are mixed-race or from an ethnic minority, as bone-marrow comes from donors that are genetically compatible. Dr. Shah is developing a method utilizing hemogenic endothelial cells (HEC) that will have the same effect, without requiring bone marrow from a matched donor. Dr. Shah is investigating FDA-approved drugs that stimulate the HECs to produce a novel and safe alternative to bone marrow-generated Hematopoietic stem cells, which will potentially treat childhood blood cancers. Awarded at the Brigham and Women's Hospital and transferred to Nationwide Children's Hospital.

Based on progress to date, Dr. Sayour was awarded a new grant in 2019 to fund an additional year of this Scholar grant. For children affected by medulloblastoma, the development of more effective and specific therapies that will not add further toxicity to existing treatments is critical in improving clinical outcomes. Dr. Sayour, the Hannah's Heroes St. Baldrick's Scholar, is investigating methods to harness the immune system to destroy these tumors though the use of nanoparticle vaccines. Nanoparticles can deliver messages to the immune system teaching it to kill cancer cells. Dr. Sayour is studying possible immune targets for nanoparticles in medulloblastoma, identifying underlying tumor resistance mechanisms, and establishing an optimum vaccine approach which he will evaluate in medulloblastoma models.

This grant is named for Hannah's Heroes, a St. Baldrick's Hero Fund created in honor of Hannah Meeson and pays tribute to her fight by raising awareness and funding for all childhood cancers.

Pediatric cancer patients that have high-risk solid tumors can be very difficult to treat, particularly when their cancer has come back after previous treatment or has spread to multiple areas of the body. Dr. Stewart is looking for specific mutations in the tumors of these patients, and testing new cancer drugs to customize treatment to give patients with relapsed high-risk solid tumors with better treatment options.

This grant is made with generous support from the Invictus Fund, a St. Baldricks's Hero Fund which was created in memory of Holden Gilkinson. It honors Holden's unconquerable spirit in his battle with bilateral Wilms tumor by funding cures and treatments to mitigate side and late effects of childhood cancer.

The human immune system is made up of a complicated network of cells including cells that help fight diseases such as cancer, and cells that prevent the immune system from fighting disease. Key cells that stop immune fighter cells from destroying cancer are called T regulatory cells (Tregs). Dr. Schultz is studying a new way to stop these Tregs and allow the good fighter cells to resume their ability to destroy cancer cells. This therapy will allow immune cells to put up a stronger fight against cancer and lead patients with cancer closer to cure.

Based on progress to date, Dr. Llosa was awarded a new grant in 2019 to fund an additional year of this Scholar grant. Osteosarcoma is a tumor that forms in the bones and is the most common bone tumor of childhood. Dr. Llosa is investigating how the immune system interacts with cancer cells from osteosarcoma tumors. Dr. Llosa's focus is on immunotherapy, a type of cancer treatment designed to boost the body's natural defenses to fight the cancer, and one of the most promising current approaches for treating tumors. Immunotherapy uses materials either made by the body or in a laboratory to improve or restore immune system function with the final goal of stopping the growth of tumors. Dr. Llosa is studying the immune microenvironment of metastatic osteosarcomas to assess their potential for checkpoint blockade (where immune responses are allowed through an checkpoint in malignant cells in order to fight the cancer) as a therapeutic option.

This grant is made with generous support from the Ethan Jostad Foundation, established by Kim and Chris Jostad in 2011 in memory of their son, Ethan, who was taken by Alveolar Rhabdomyosarcoma at the age of nine. In addition to funding cutting-edge pediatric cancer research, the foundation's mission is to provide emotional and financial support to children and families impacted by the disease.

Telomeres are special sequences of DNA located at the ends of every chromosome, and are essential to maintaining proper cellular function. If telomeres are damaged or degraded, they may cause healthy cells to transform into cancer cells. Dr. O'Sullivan and his team have discovered a protein called RAD51AP1 that appears at high levels in neuroblastoma tumor cells, and they have determined that having less of this protein stops telomere damage in cells. Dr. O'Sullivan is investigating the consequences and impact of RAD51AP1 inhibition on the proliferation and survival of neuroblastoma tumor cells.